GPT and metabolic dysfunction-associated steatotic liver disease: Based on proposed criteria, two groups were identified: (I) NAFLD patients (N = 49; 45.4%) and (II) non-NAFLD patients with normal liver and normal ALT concentration (N = 59; 54.6%).